The results has been filter on Tags containing Evaluation.
ANA has found 91 results for you, in
510 ms.
Currently showing results 55 to 63.
Didn’t find what you were looking for? Try the Advanced Search!
Bronner, A. E. (1990a, September 01). The end of fusion fear?. ANA - ESOMAR. Retrieved September 25, 2024, from
https://ana.esomar.org/documents/the-end-of-fusion-fear-
Lindon and Boss (1990a, September 01). How to measure and improve the performance of the marketing research function within user companies? (French). ANA - ESOMAR. Retrieved September 25, 2024, from
Lindon and Boss (1990a, September 01). How to measure and improve the performance of the marketing research function within user companies?. ANA - ESOMAR. Retrieved September 25, 2024, from
Ramsay, B. (1990a, June 15). The challenges and opportunities for new product development in the FMCG industry. ANA - ESOMAR. Retrieved September 25, 2024, from
B.V., A. (1990a, January 01). ARF criteria for marketing and advertising research . ANA - ESOMAR. Retrieved September 25, 2024, from
https://ana.esomar.org/documents/arf-criteria-for-marketing-and-advertising-research-
B.V., A. (1990a, January 01). Guidelines for the public use of market and opinion research . ANA - ESOMAR. Retrieved September 25, 2024, from
https://ana.esomar.org/documents/guidelines-for-the-public-use-of-market-and-opinion-research-
Hayes and Otker (1987a, September 01). Judging the efficiency of sponsorship. ANA - ESOMAR. Retrieved September 25, 2024, from
https://ana.esomar.org/documents/judging-the-efficiency-of-sponsorship
Hertzman, P. (1987a, June 15). A model for a cost-benefit analysis of a new pharmaceutical. ANA - ESOMAR. Retrieved September 25, 2024, from
https://ana.esomar.org/documents/a-model-for-a-cost-benefit-analysis-of-a-new-pharmaceutical
Biggs, H. (1987a, June 15). Farmad. ANA - ESOMAR. Retrieved September 25, 2024, from
https://ana.esomar.org/documents/farmad